Contributions
Abstract: EP1652
Type: Poster Sessions
Abstract Category: Therapy - Long-term treatment monitoring
Introduction: Natalizumab and Fingolimod are two second-line treatments that are significantly more effective than first-line treatments. Given the benefit / risk ratio of these two treatments, it seems useful to compare their effectiveness to guide the choice of treatment for patients with relapsing-remitting multiples sclerosis (RRMS).
Methods: This is a retrospective study of 80 patients followed for RRMS in the Neurology department of Habib Bourguiba Hospital in Sfax and in the Neurology department of Razi Hospital in Manouba. Comparative efficacy data between Natalizumab and Fingolimod were judged by the annualized relapse rate (ARR), Expanded Disability Status Scale score (EDSS), Multiple Sclerosis Severity Score (MSSS) and by reducing or stabilizing of lesions in brain and/or spinal magnetic resonance imaging (MRI).
Results: The mean age of patients at the beginning of second-line treatment was 34.25 ± 9.1 years [17-59]. The mean age at introduction of Natalizumab was 30.6 ± 7.4 years [17-50]. The mean age at introduction of Fingolimod was 37.4 ± 9.4 years [21 - 59]. This difference was statistically significant (p < 0.0001). The percentage of patients treated with Natalizumab and remaining free from relapses was comparable to that seen in patients treated with Fingolimod. We have seen a better efficacy of Natalizumab in reducing ARR compared to Fingolimod (93% vs 79%) (p = 0.026). The percentage of patients remaining free of EDSS progression was similar between the two molecules. An improvement in EDSS score was seen in 36% and in 11% under Natalizumab and Fingolimod respectively (p=0.014). The percentage of patients remaining free from radiological activity was greater in those who received Natalizumab (p = 0.002). The percentage of patients free of clinical and radiological activity was 60.5% and 41%, respectively, after two years of treatment with Natalizumab and Fingolimod (p = 0.017).
Conclusion: Natalizumab and Fingolimod showed better efficacy compared to first-line treatments. However, Natalizumab appears to have better clinical and radiological efficacy compared to Fingolimod.
Disclosure: Ahmed Ghariani: noting to disclose
Mariem Damak: noting to disclose
Amina Nasri: noting to disclose
Olfa Hdiji: noting to disclose
Saloua Mrabet: noting to disclose
Salma Sakka: noting to disclose
Mouna Ben Djebara: noting to disclose
Riadh Gouider: noting to disclose
Chokri Mhiri: noting to disclose
Abstract: EP1652
Type: Poster Sessions
Abstract Category: Therapy - Long-term treatment monitoring
Introduction: Natalizumab and Fingolimod are two second-line treatments that are significantly more effective than first-line treatments. Given the benefit / risk ratio of these two treatments, it seems useful to compare their effectiveness to guide the choice of treatment for patients with relapsing-remitting multiples sclerosis (RRMS).
Methods: This is a retrospective study of 80 patients followed for RRMS in the Neurology department of Habib Bourguiba Hospital in Sfax and in the Neurology department of Razi Hospital in Manouba. Comparative efficacy data between Natalizumab and Fingolimod were judged by the annualized relapse rate (ARR), Expanded Disability Status Scale score (EDSS), Multiple Sclerosis Severity Score (MSSS) and by reducing or stabilizing of lesions in brain and/or spinal magnetic resonance imaging (MRI).
Results: The mean age of patients at the beginning of second-line treatment was 34.25 ± 9.1 years [17-59]. The mean age at introduction of Natalizumab was 30.6 ± 7.4 years [17-50]. The mean age at introduction of Fingolimod was 37.4 ± 9.4 years [21 - 59]. This difference was statistically significant (p < 0.0001). The percentage of patients treated with Natalizumab and remaining free from relapses was comparable to that seen in patients treated with Fingolimod. We have seen a better efficacy of Natalizumab in reducing ARR compared to Fingolimod (93% vs 79%) (p = 0.026). The percentage of patients remaining free of EDSS progression was similar between the two molecules. An improvement in EDSS score was seen in 36% and in 11% under Natalizumab and Fingolimod respectively (p=0.014). The percentage of patients remaining free from radiological activity was greater in those who received Natalizumab (p = 0.002). The percentage of patients free of clinical and radiological activity was 60.5% and 41%, respectively, after two years of treatment with Natalizumab and Fingolimod (p = 0.017).
Conclusion: Natalizumab and Fingolimod showed better efficacy compared to first-line treatments. However, Natalizumab appears to have better clinical and radiological efficacy compared to Fingolimod.
Disclosure: Ahmed Ghariani: noting to disclose
Mariem Damak: noting to disclose
Amina Nasri: noting to disclose
Olfa Hdiji: noting to disclose
Saloua Mrabet: noting to disclose
Salma Sakka: noting to disclose
Mouna Ben Djebara: noting to disclose
Riadh Gouider: noting to disclose
Chokri Mhiri: noting to disclose